Neil Vasan - Concepedia

Author

Neil Vasan

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

N Vasan, N. Vasan, Neil Vasan, Neil Vasan

107

Publications

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Columbia University Irving Medical Center Massachusetts Institute of Technology Columbia University

About

Neil Vasan is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, tumor microenvironment, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	657
2	Natural Sciences	2	2	64
3	Biochemistry	2	2	172
4	Cell Biology	2	2	111
5	Engineering	1	1	68

Neil Vasan

Publications

Citations

H-Index

Page 1

	Year	Citations
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers Pedram Razavi, Matthew T. Chang, Guotai Xu, Cancer Cell Breast OncologyGenomic LandscapeCancer GenomicsBreast CancerRadiation Oncology	2018	956
An atlas of substrate specificities for the human serine/threonine kinome Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Nature	2023	621
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors Neil Vasan, Pedram Razavi, Jared L. Johnson, Science	2019	281
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis Jun Li, Mercedes A. Duran Paez, Ninjit Dhanota, Cancer Discovery	2020	264
Dietary fructose improves intestinal cell survival and nutrient absorption Samuel Taylor, Shakti Ramsamooj, Roger J. Liang, Nature NutritionCellular NutritionPhysiologyGastroenterologyDietary Fibre	2021	259
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors Pedram Razavi, Maura N. Dickler, Payal D. Shah, Nature Cancer Clinical ResistanceBiochemistryMedicineMechanism Of ActionAromatase	2020	155
The intrinsic substrate specificity of the human tyrosine kinome Tomer M. Yaron, Brian A. Joughin, Emily M. Huntsman, Nature	2024	115
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity Patricia Ho, Johannes C. Melms, Meri Rogava, Cancer Cell Cancer ImmunosurveillanceCd58-cd2 AxisImmunologyTumor ImmunityImmunologic Mechanism	2023	84
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice Neil Vasan, Roman Yelensky, Kai Wang, The Oncologist Breast OncologyEngineeringPathologyHigh FrequencyTumor Biology	2014	68
Phase and context shape the function of composite oncogenic mutations Alexander N. Gorelick, Francisco J. Sánchez‐Rivera, Yanyan Cai, Nature Genome InstabilitySomatic VariantNatural SciencesGeneticsGenomic Mechanism	2020	47

Page 1